[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3327
1. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM: Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood; 2008 Apr 1;111(7):3377-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma.
  • Young adult Hodgkin lymphoma (YAHL) is associated clinically with altered immunity, including a systemic defect in cell-mediated responses.
  • We identified twin pairs in whom at least one member had YAHL and measured interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-gamma) levels in PHA-stimulated peripheral blood mononuclear cell supernatant in 90 case-twins, 84 of their disease-free twins (unaffected cotwins), and 90 matched controls.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Oct 15;175(8):5457-62 [16210653.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Genes Immun. 2000 Dec;1(8):515-20 [11197695.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):218-21 [11175794.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Twin Res. 2001 Aug;4(4):242-50 [11665304.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):69-75 [11905816.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):545-52 [12845650.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Biometrics. 1982 Sep;38(3):715-24 [7171697.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):673-82 [2251514.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):174-7 [8700209.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1658-65 [9257825.001]
  • [Cites] Genes Immun. 2004 Dec;5(8):675-7 [15483662.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1432-6 [15603869.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):740-8 [15643599.001]
  • [Cites] Genes Immun. 2005 Mar;6(2):167-70 [15674372.001]
  • [Cites] Intensive Care Med. 2005 Mar;31(3):401-7 [15719148.001]
  • [Cites] Cytokine. 2005 May 21;30(4):188-94 [15863393.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):125-35 [16510856.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2062-3 [16990781.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • (PMID = 18077789.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2275007
  •  go-up   go-down


2. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


3. Massini G, Siemer D, Hohaus S: EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV in Hodgkin Lymphoma.
  • Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein-Barr virus (EBV).
  • Clonal viral genomes can be found in the HL tumor cells, the Hodgkin Reed-Sternberg cells (HRS).
  • The presence of EBV in HL is associated with several clinicopathological characteristics: It is more frequent in cases with mixed cellular histology, in males, in children and older adults, and in developing countries, while the young-adult onset HL of nodular sclerosis type in industrialized countries is typically EBV-negative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 15;106(13):4345-50 [16131568.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1650-5 [16983344.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Lett. 2008 Oct 18;270(1):66-76 [18539384.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1499-507 [18646185.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] J Infect Dis. 1979 May;139(5):553-8 [220340.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):929-31 [2594086.001]
  • [Cites] J Infect Dis. 1971 Mar;123(3):263-70 [4329526.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):471-3 [4348499.001]
  • [Cites] Wistar Inst Symp Monogr. 1965 Sep;4:69-82 [5884338.001]
  • [Cites] Arch Virol. 1998;143(4):803-13 [9638150.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Pathol. 1999 Feb;187(3):326-30 [10398087.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4249-52 [16123211.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:61-80 [16909907.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1376-81 [17496310.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5771-8 [17575144.001]
  • [Cites] J Virol. 2007 Sep;81(18):10092-100 [17626071.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1470-4 [18024394.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1342-9 [18042690.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8225-34 [18056366.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):716-9 [18470916.001]
  • [Cites] Virology. 1991 Apr;181(2):595-608 [1849678.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1769-77 [18661399.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6974-8 [18980992.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1352-6 [19201467.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] J Virol. 1997 Jul;71(7):4882-91 [9188550.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6959-64 [10602470.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1579-87 [11301409.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1227-34 [11336475.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3964-73 [11359904.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):199-204 [11122844.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1853-7 [11576839.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):282-90 [12562657.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):159-65 [14530808.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3060-2 [11929801.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Virol. 2000 Nov;74(22):10468-79 [11044091.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] J Pathol. 2005 May;206(1):68-75 [15751051.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] Saudi Med J. 2005 Apr;26(4):571-5 [15900362.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):53-63 [14585276.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Virol. 1995 Jun;69(6):3752-8 [7745723.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1360-6 [7882287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):359-63 [8397160.001]
  • [Cites] Mod Pathol. 1995 Aug;8(6):675-9 [8532705.001]
  • [Cites] Arch Dis Child. 1996 Jan;74(1):27-31 [8660041.001]
  • [Cites] Immunity. 1996 Aug;5(2):173-9 [8769480.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):138-41 [9139832.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cell. 1979 Jul;17(3):661-71 [225039.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Exp Med. 1988 Dec 1;168(6):2059-75 [2848918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 [5242134.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2447-51 [7919364.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Blood. 1993 Jan 15;81(2):496-501 [8380728.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):781-4 [8631592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6611-6 [15096587.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2138-46 [15933052.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):251-61; quiz 262 [16083776.001]
  • (PMID = 21416003.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033177
  •  go-up   go-down


Advertisement
4. Hjalgrim H, Seow A, Rostgaard K, Friborg J: Changing patterns of Hodgkin lymphoma incidence in Singapore. Int J Cancer; 2008 Aug 1;123(3):716-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing patterns of Hodgkin lymphoma incidence in Singapore.
  • A bimodal age-specific incidence pattern with a relatively high proportion of cases occurring in adolescents and young adults is a hallmark of Hodgkin lymphoma (HL) epidemiology in Western industrialized countries.
  • The young adult incidence peak is believed to reflect the association between HL risk in young adults and an affluent childhood socioeconomic environment.
  • However, the dynamic development of the young adult incidence peak following socioeconomic development implied by this interpretation has scarcely been demonstrated in a single population over time.
  • As hypothesized a HL incidence peak emerged among adolescents and young adults in Singapore.
  • However, the incidence peak remained considerably lower than what can be observed in young adults in the Western World.
  • It remains to be determined to what extent the current lower incidence of HL in young Asian adults should be attributed to birth cohort phenomena, as would be suggested by continued increase in incidence, and to ethnic variation in HL susceptibility between Asian and non-Asian populations, respectively.
  • [MeSH-major] Hodgkin Disease / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Confidence Intervals. Female. Genetic Predisposition to Disease. Humans. Incidence. Infant. Male. Middle Aged. Poisson Distribution. Singapore / epidemiology. Socioeconomic Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470916.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


6. Yi WS, Xu XL, Xiang Q, Jiang HB: [Characteristics of ocular adnexal non-Hodgkin lymphoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;33(9):826-30
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of ocular adnexal non-Hodgkin lymphoma].
  • OBJECTIVE: To investigate the clinical manifestation and pathological features of primary ocular adnexal non-Hodgkin lymphoma.
  • METHODS: Data of 18 patients with biopsy-proven ocular adnexal non-Hodgkin lymphoma at Xiangya hospital were reviewed.The disease site, clinical manifestation,imaging and pathological features of the tumor were summarized.
  • RESULTS: All patients had typical presentation of an adnexal mass.Twelve(66.7%) patients had orbital involvement, 3(16.7%) had conjunctival, and 3(16.7%) had lymphoma involving the eyelids.Eight patients were misdiagnosed as "inflammatory pseudotumour" before the operation according to their clinical and imaging examination,another 8 patients were diagnosed as "ocular adnexal tumour with unknown nature" before the operation.
  • According to the pathologic diagnosis, 16 patients (88.9%)had marginal zone lymphomas of mucosa-associated lymphoid tissue(MZL-MALT) and 2 (11.1%) had NK/T-cell lymphoma.
  • CONCLUSION: The typical presentation of ocular adnexal lymphoma is a painless mass.Orbital connective tissue is the most involved anatomical site.
  • The diagnosis of ocular adnexal non-Hodgkin lymphoma is difficult which could easily be misdiagnosed as "inflammatory pseudotumour".
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812662.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


7. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT: CNS Hodgkin lymphoma. Blood; 2008 Sep 1;112(5):1658-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS Hodgkin lymphoma.
  • Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare.
  • Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse.
  • Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Middle Aged. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] Radiat Med. 2000 May-Jun;18(3):205-8 [10972552.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):387-8; 393 [11414479.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1667-71 [15370222.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3182 [17634503.001]
  • [Cites] Cancer. 1979 Apr;43(4):1497-506 [376094.001]
  • [Cites] Cancer. 1983 Oct 1;52(7):1301-7 [6883291.001]
  • [Cites] Clin Lab Haematol. 1989;11(4):331-8 [2605874.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1437-8 [17416864.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4228-30 [15483035.001]
  • (PMID = 18591379.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710443
  •  go-up   go-down


8. Wilson KS, Gallagher A, Freeland JM, Shield LA, Jarrett RF: Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies. Leuk Lymphoma; 2006 Jul;47(7):1315-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies.
  • The epidemiology of young adult Hodgkin lymphoma (HL) suggests that delayed exposure to a common childhood pathogen may be involved in disease pathogenesis.
  • The Epstein-Barr virus (EBV) is associated with a proportion of cases but cases of young adult HL in westernized countries are less frequently EBV-associated than cases in other age groups and geographical locales.
  • [MeSH-major] Genome, Viral. Hodgkin Disease / virology. Polyomavirus / genetics
  • [MeSH-minor] Adult. Aged. Biopsy. DNA Primers / chemistry. Female. Herpesvirus 4, Human / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY911513
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


9. Negri E: Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma. Nutr Cancer; 2010;62(7):878-82
MedlinePlus Health Information. consumer health - Vitamin D.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma.
  • Similarities in the epidemiology of melanoma, other skin cancers, and non-Hodgkin lymphoma (NHL) have led to the hypothesis that UV exposure, the major risk factor for cutaneous cancers, could play a role on NHL risk too.
  • The paucity of information on the relation of sun exposure or vitamin D with adult Hodgkin lymphoma (HL) or childhood lymphomas prevents any definite conclusion.
  • [MeSH-major] Lymphoma, Non-Hodgkin / etiology. Sunlight / adverse effects. Vitamin D / analogs & derivatives
  • [MeSH-minor] Disease Susceptibility. Humans. Risk Factors. SEER Program

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924963.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D
  •  go-up   go-down


10. Freed J, Kelly KM: Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs; 2010 Apr 1;12(2):85-98
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approaches to the management of pediatric Hodgkin lymphoma.
  • Hodgkin lymphoma is one of the few cancers that affect both adults and children.
  • Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers.
  • At diagnosis, patients are classified into risk groups based on disease stage, and the presence of clinical, biologic, and serologic risk factors.
  • In general, the most recent trials have intensified therapy in those patients with high-risk disease to improve disease control, and have limited therapy in those patients with low-risk disease to avoid secondary effects.
  • In addition, response assessment by fluorine-18-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) may be particularly important in pediatric Hodgkin lymphoma; it may allow modification of treatment to maximize treatment efficacy and minimize late effects of chemotherapy and radiation therapy.
  • Despite the improvements in treatment for all stages of Hodgkin lymphoma, there is still a subgroup of patients who do not enter remission with initial therapy or relapse after initial response to therapy.
  • Unfortunately, standard-dose salvage chemotherapy for relapsed disease has disappointing results in terms of overall survival since patients have typically already received intensive therapy.
  • While there is no standard of care in terms of salvage chemotherapy, high-dose chemotherapy with autologous stem cell transplant (ASCT) rescue has become the standard of care for the majority of children with relapsed Hodgkin lymphoma.
  • The use of allogeneic transplantation is controversial in relapsed or refractory Hodgkin lymphoma; because of the high transplant-related mortality, allogeneic transplant has not been associated with improved overall survival over ASCT.
  • As more has been learned about the biologic mechanisms involved in Hodgkin lymphoma, biologically-based therapies are being investigated for use in this disease, both at initial diagnosis and relapse.
  • Both immunotherapy and small molecules are being studied as possible therapeutic agents in Hodgkin lymphoma.
  • Unfortunately, the vast majority of investigations of novel agents have occurred exclusively in adult patients.
  • However, since pediatric Hodgkin lymphoma and adult Hodgkin lymphoma are similar, these results may potentially be extrapolated to pediatric Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Neoplasm Staging. Remission Induction / methods. Risk Factors. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218745.001).
  • [ISSN] 1179-2019
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 73
  •  go-up   go-down


11. Müller J, Molnár Z, Illés A, Csóka M, Jakab Z, Deák B, Schneider T, Várady E, Rosta A, Simon Z, Keresztes K, Gergely L, Kovács G: [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?]. Orv Hetil; 2008 Nov 23;149(47):2221-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?].
  • [Transliterated title] Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: felnôtt- vagy gyermekintézményben?
  • Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards.
  • AIM: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes.
  • METHODS: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P).
  • Event-free survival was higher in pediatric than in adult institutes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Care Facilities / statistics & numerical data. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Hungary / epidemiology. Male. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004744.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; OPPA protocol
  •  go-up   go-down


12. Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M: [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions]. Orv Hetil; 2009 Aug 30;150(35):1649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
  • [Transliterated title] Pimer gastrointestinalis non-Hodgkin-lymphoma két magyarországi régió beteganyaga alapján.
  • Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased.
  • The treatment strategy for non-Hodgkin's lymphoma has changed over the past decade: chemo-immunotherapy has largely taken over surgical intervention, the dominant treatment option of the past.
  • METHODS: The authors present their experience with 48 patients with non-Hodgkin's lymphoma, affecting the gastrointestinal tract, treated in Kaposvár, in the Kaposi Mór Teaching Hospital and in Gyula, in the Pándy Kálmán County Hospital.
  • RESULTS: The most frequently involved GI organ was the stomach ( n = 26), with the dominant histological type of diffuse large B-cell lymphoma.
  • Patients with upper gastrointestinal tract involvement carried the best prognosis (IPI: 2.0); at the same time, patients with stomach lymphoma achieved the highest rate of remission (73%).
  • CONCLUSIONS: With chemo-immunotherapy the chances of a complete remission have significantly improved over the past decade, thus a significant portion of non-Hodgkin's lymphomas involving the gastrointestinal tract can be cured.
  • IPI index represents the most recognised indicator for assessing the prognosis of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Hungary / epidemiology. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692309.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


13. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Jóna A, Illés A: [Changing patterns in the clinical, pathological features of Hodgkin lymphoma]. Orv Hetil; 2010 Dec 5;151(49):2011-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing patterns in the clinical, pathological features of Hodgkin lymphoma].
  • [Transliterated title] Változnak-e a Hodgkin-lymphoma klinikopatológiai jellemzői?
  • Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
  • PATIENTS AND METHODS: The Authors analyzed 439 Hodgkin lymphoma patients' clinicopathological and treatment data.
  • RESULTS: The first period contained 117 patients, the second 147 and third 115 Hodgkin lymphoma patients.
  • CONCLUSIONS: Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Socioeconomic Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21106481.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


14. Yayan J, Mallouhi A, Moser P, Irschick E: [Non-Hodgkin lymphoma of the lacrimal gland]. Ophthalmologe; 2008 Sep;105(9):852-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma of the lacrimal gland].
  • [Transliterated title] Non-Hodgkin-Lymphom der Tränendrüse.
  • BACKGROUND: Non-Hodgkin lymphoma is a systemic disease and various organs can therefore be affected.
  • Ocular manifestations of non-Hodgkin lymphomas are possible but involvement of the eyelids or lacrimal glands are uncommon.
  • The histologic examination revealed a recurrent non-Hodgkin lymphoma.
  • In the case described here it was interesting that behind a painless eyelid swelling even a systemic disorder was hidden, i.e. a recurrence of a non-Hodgkin lymphoma, which was localized in the lacrimal gland.
  • [MeSH-major] Eye Neoplasms. Lacrimal Apparatus. Lymphoma, Follicular
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Diagnosis, Differential. Edema / etiology. Eyelid Diseases / etiology. Female. Humans. Immunotherapy. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Rituximab. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373097.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Illés A: [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience]. Orv Hetil; 2010 Jan 31;151(5):172-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy for patients with primary refractory and relapsed Hodgkin-lymphoma--our experience].
  • [Transliterated title] Refrakter és relabált Hodgkin-lymphomás betegeink kezelésével szerzett tapasztalataink.
  • Recovery have been achieved in the majority of Hodgkin-lymphoma patients.
  • AIM AND METHODS: We investigated the frequency and treatment of refracter or relapsed Hodgkin lymphoma patients between 1996 and 2006.
  • 6 of the relapsed patients were died, 5 because of the progression of lymphoma and one because of secunder myelodysplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Recurrence. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083465.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


16. Henderson TO, Hlubocky F, Diller L, Daugherty C: Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol; 2009 May 20;27(15_suppl):6561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 84% of respondents report eventually referring CCS to a LTFU program (40%), to a primary care physician (23%) or to an adult oncologist (12%).
  • In a clinical vignette of 29 year old women exposed to mantle radiation and anthracyclines (150 mg/m2) for Hodgkin's lymphoma at 16 years of age: 30% of respondents did not appropriately recommend yearly breast cancer surveillance (based on Children's Oncology Group LTFU guidelines); 41% of respondents did not appropriately recommend cardiac surveillance; and 15% of respondents did not appropriately recommend yearly thyroid screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • 8 patients (32%) had stable disease and 12 (48%) progressed on treatment.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • It can mitigate symptoms resulting from bulky disease and shows potential as a palliative treatment option.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Tan H, Tomic K, Daniel G, Hurley D, Barron R: Evaluating risk of hospitalization with G-CSF use in real-world oncology practice. J Clin Oncol; 2009 May 20;27(15_suppl):6626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ: Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol; 2009 May 20;27(15_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
  • : 8547 Background: Increased late mortality and morbidity have been observed among adult survivors of Hodgkin lymphoma (HL) treated in childhood, but are less well characterized for patients treated in adulthood.
  • METHODS: We investigated the late mortality and morbidity of adult patients treated at our center from 1975 to 2000.
  • The most prevalent severe morbidities included second primary malignancy (SPM) (17%), cardiovascular (CV) (18%) and neurologic (18%) disease.
  • CONCLUSIONS: Among adults treated on trials of CMT, by 22y post-treatment the risk of death due to HL is surpassed by risk of death due to other causes.
  • These findings underscore the importance of efforts directed at prevention of and early intervention for late morbidity in adult survivors of HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Dögel D, Beuing O, Koenigsmann M, Diete S: [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr; 2008 Jan;76(1):41-6
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
  • [Transliterated title] Paraneoplastische Limbische Enzephalitis als Erstmanifestation eines malignen Non Hodgkin Lymphoms.
  • Paraneoplastic limbic encephalitis (PLE) is a rare disease that is probably caused by an immunological reaction against CNS-structures.
  • Besides treatment of the underlying neoplastic disease, there is no generally applicable evidence-based treatment.
  • PLE is most frequently associated with certain carcinomas, but its occurrence with Hodgkin lymphoma has also been recognized.
  • Association with non-Hodgkin lymphoma has only been occasionally reported in single cases.
  • We report two additional patients, in whom malignant non-Hodgkin lymphomas of the B- and T-cell lines were detected.
  • [MeSH-major] Limbic Encephalitis / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189222.001).
  • [ISSN] 0720-4299
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


22. Molnár Z, Simon Z, Borbényi Z, Deák B, Galuska L, Keresztes K, Miltényi Z, Marton I, Rosta A, Schneider T, Trón L, Várady E, Illés A: [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results]. Orv Hetil; 2009 Nov 22;150(47):2133-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results].
  • [Transliterated title] Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink.
  • In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Radiopharmaceuticals. Recurrence. Remission Induction. Retrospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910278.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Beck Z, Illés A, Keresztes K, Bessenyei B, Szöllosi Z, Kis A, Oláh E: [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?]. Orv Hetil; 2006 Aug 20;147(33):1539-44
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ZEBRA protein of Epstein-Barr virus in Hungarian patients with Hodgkin lymphoma: latent or lytic cycle?].
  • [Transliterated title] Az Epstein-Barr-vírus ZEBRA fehérjéjének expressziója magyarországi Hodgkin-lymphomás betegekben: latens vagy litikus ciklus?
  • The virus is associated with an increasing number of lymphoid malignancies, such as Hodgkin and non-Hodgkin lymphomas.
  • Although the presence of ZEBRA protein induces lytic cycle, some lymphoma cases show this protein expression.
  • AIM: In our present study we investigated the frequency of expression of ZEBRA protein in Hungarian patients with Hodgkin lymphoma associated with Epstein-Barr virus infection.
  • The authors wanted to clarify whether this expression is specific to latency type II or occurs in some non-Hodgkin lymphoma cases with latency type III as well.
  • We detected the weak expression of ZEBRA protein in 13 of the 25 LMP1 positive Hodgkin lymphoma cases and in 6 of the 18 LMP1 positive non-Hodgkin lymphoma samples.
  • CONCLUSION: In the examined group of patients the ZEBRA positivity associated with a poor prognosis of the disease.
  • [MeSH-major] DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / virology. Trans-Activators / analysis. Viral Proteins / analysis
  • [MeSH-minor] Adult. Aged. Epstein-Barr Virus Nuclear Antigens / analysis. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Hungary. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17037676.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA-Binding Proteins; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  •  go-up   go-down


24. Keresztes K, Bessenyei B, Szöllosi Z, Beck Z, Miltényi Z, Nemes Z, Oláh E, Illés A: [Association of Hodgkin lymphoma with Epstein-Barr virus in Hungary]. Orv Hetil; 2005 Jul 24;146(30):1575-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of Hodgkin lymphoma with Epstein-Barr virus in Hungary].
  • [Transliterated title] Hodgkin-lymphomfás betegek Epstein-Barr-virus-asszociációjának vizsgálata.
  • INTRODUCTION: The occurrence of Epstein-Barr virus associated Hodgkin's lymphoma shows considerable variation from continent to continent and from country to country but in Hungary no such investigations have been performed so far.
  • AIM: The authors analyse the presence of Epstein-Barr virus and the type of latency in histologic samples taken from Hodgkin's disease patients.
  • Epstein-Barr virus association did not show any alteration in children (1-14 years) when compared to that of adults (out of the 10 children 6 were positive by PCR).
  • On examining Hodgkin's lymphoma and Epstein-Barr virus association disease models, they could not categorize their patients into any of them though characteristic patient groups could be more or less observed also in their material.
  • CONCLUSION: These results indicate that Epstein-Barr infection may play an important role in the development of Hodgkin's lymphoma in Hungary, too.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Hungary / epidemiology. Immunohistochemistry. In Situ Hybridization. Infant. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136734.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


25. Herbertson R, Hancock BW: Hodgkin Lymphoma in adolescents. Cancer Treat Rev; 2005 Aug;31(5):339-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin Lymphoma in adolescents.
  • With the development of an integrated treatment approach, the cure rate and survival of patients with Hodgkin Lymphoma (HL) is now high.
  • Future treatment strategies may direct the treatment of adolescents with HL away from the current "adult" regimens, and closer to that currently received by children, but prospective randomised trials are required.
  • [MeSH-major] Hodgkin Disease

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951118.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


26. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


27. Viscasillas Pallás G, Cisa Lluís E, Cruellas Taischik F, Doménech Juan I, Dicenta Sousa M: [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma]. An Otorrinolaringol Ibero Am; 2005;32(1):23-8
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a case of cervical actinomycosis versus Hodgkin lymphoma].
  • [Transliterated title] Actinomicosis cervical versus linfoma de Hodgkin. A propósito de un caso.
  • We present the case of a young patient affected by a cervical tumoration initially oriented as Hodgkin lymphoma that finally was diagnosed as cervical actinomycosis and treated with penicillin.
  • [MeSH-major] Actinomycosis / diagnosis. Actinomycosis / microbiology. Cervical Vertebrae / microbiology. Hodgkin Disease / diagnosis. Propionibacterium / isolation & purification
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed


28. Lechner K, Chen YA: Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma. Leuk Lymphoma; 2010 Mar;51(3):469-74
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma.
  • We assessed the occurrence, clinical, and laboratory features as well as the response to treatment of autoimmune hemolytic anemia, autoimmune thrombocytopenia, and neutropenia in published cases of Hodgkin lymphomas (HL).
  • The autoimmune cytopenias (AIC) may occur prior to, concurrent with, at the time of recurrence of lymphoma or in complete remission after treatment.
  • HL is the only lymphoma which may be associated with autoimmune neutropenia.
  • In contrast to AIC in diffuse large B-cell lymphoma (DLBCL), early stage is less common in patients with HL with AIC.
  • [MeSH-major] Autoimmune Diseases / complications. Hodgkin Disease / complications. Neutropenia / complications. Thrombocytopenia / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. PubMed. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141438.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


29. Padilla GF, Garibay MA, Hummel HN, Avila R, Méndez A, Ramírez R: [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review]. Acta Gastroenterol Latinoam; 2009 Jun;39(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant non-Hodgkin lymphoma presenting as lactic acidosis and acute liver failure: case report and literature review].
  • [Transliterated title] Linfoma no Hodgkin fulminante presentándose con acidosis láctica e insuficiencia hepática aguda: reporte de caso y revisión de la literatura.
  • Hematological malignancies, as leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma, typically do not result in hepatic dysfunction and rarely manifest as fulminant liver failure.
  • CONCLUSIONS: Acute liver failure is uncommon as the presenting feature of lymphoma.
  • Given the poor prognosis associated with late or missed diagnosis and the potential benefits of early chemotherapy, lymphoma should be considered in any patient presenting with acute liver failure without an obvious etiology and associated with lactic acidosis and hepatomegaly.
  • [MeSH-major] Acidosis, Lactic / etiology. Liver Failure, Acute / etiology. Liver Neoplasms / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663087.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 41
  •  go-up   go-down


30. Möller P, Mader A, Barth TF, Brüderlein S: [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma]. Pathologe; 2008 Nov;29 Suppl 2:317-8
Cellosaurus - a cell line knowledge resource. culture/stock collections - U-HO1 (CVCL_2220) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma].
  • [Transliterated title] U-HO1. Eine neue Zelllinie, abstammend von einem primär therapierefraktären klassischen Hodgkin-Lymphom.
  • The Hodgkin cell line U-HO1 was established from a malignant pleural effusion of a 23-yr-old male patient during the end stage of refractory nodular sclerosing classical Hodgkin lymphoma (cHL).
  • [MeSH-major] Cell Line, Tumor. Hodgkin Disease / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Allelic Imbalance / genetics. Cell Division / genetics. Cell Division / physiology. Chromosomes, Human, Pair 2 / genetics. Combined Modality Therapy. Drug Resistance, Neoplasm / genetics. HLA-D Antigens / analysis. Humans. Male. Phenotype. Reed-Sternberg Cells / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820924.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA-D Antigens
  •  go-up   go-down


31. Halilbasić A, Mesic E, Cikusić E, Arnautović A: [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]. Med Arh; 2006;60(6 Suppl 2):78-83
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease].
  • [Transliterated title] Non Hodgkin limfom u Sjeveroistoinoj Bosni--promjene u bioloskoj agresivnosti i nacinu primarne prezentacije.
  • These factors were analysed: immunophenotype NHL by immunohistochemical method of indirect three-stage immunoperoxidase with streptovidin, the type of NHL, the degree of biological aggressiveness of NHL, the way of primary presentation and the clinical phases of distribution of the disease according to the age, sex, profession and the habitat (urban or rural) of the patients.
  • The prevalence and the incidence of the disease in the region of the North-East Bosnia was determined.
  • Diffuse Large Cell Lymphoma (DLCL) was dominant in the test group with total of 73 patients (51%), and Small Cell Lymphoma was dominant in the control group with total of 33 patients (38%).
  • Statistically significant increase of both DLCL and MALT lymphoma is found in the test group (p < 0.025), and the most frequent were patients with IV-B (18%), I-AE (15%) and II-BE (12%) clinical stadium, while in the control group the most frequent number of patients was in the clinical studia III-B (19%), II-B (14%) and IV-B (14%).
  • In the test group there was a significant increase of aggressive lymphoma in both men and women (p < 0.01).
  • In the test group the number of MALT and DLCL lymphoma located in stomach is in increase.
  • Therefore the significant increase of the patients with this disease is noticed in our test group.
  • CONCLUSION: The incidence of NHL in the region of the North East Bosnia follows the world trend of the general increase of the NHL incidence including the significant increase in number of aggressive lymphoma.
  • The frequency of DLCL and MALT lymphoma is evidently in increase.
  • The significant changes in primary presentation of the disease have not been noticed.
  • [MeSH-major] Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adolescent. Adult. Aged. Bosnia and Herzegovina / epidemiology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172989.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


32. Benharroch D, Einav I, Feldman A, Levy A, Ariad S, Gopas J: Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited. APMIS; 2010 May;118(5):339-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis of Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma revisited.
  • We scrutinized the role of apoptosis of the Hodgkin-Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) and critically reviewed its features in the light of conflicting evidence.
  • These findings support our contention that the role of apoptosis in the HRS cells of Hodgkin lymphoma has not been completely elucidated and is at variance with that in the consensus.
  • [MeSH-major] Apoptosis / physiology. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Herpesvirus 4, Human / metabolism. Herpesvirus 4, Human / pathogenicity. Humans. Immunohistochemistry. Male. Middle Aged. NF-kappa B / metabolism. Viral Matrix Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477808.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  • [Number-of-references] 29
  •  go-up   go-down


33. Sharma A, Gupta D, Mohanti BK, Thulkar S, Dwary A, Goyal S, Muzumder S, Das P: Non-Hodgkin lymphoma following temozolomide. Pediatr Blood Cancer; 2009 Oct;53(4):661-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma following temozolomide.
  • Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported.
  • We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy.
  • She developed lymphoma 2 months after completing chemoradiotherapy.
  • Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Dacarbazine / analogs & derivatives. Lymphoma, Non-Hodgkin / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Adult. Female. Glioblastoma / drug therapy. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533661.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


34. Wiecheć M, Kempf Haber M, Załuska A, Klimek M, Skotnicki AB: [Non Hodgkin lymphoma during pregnancy]. Ginekol Pol; 2005 Feb;76(2):135-40
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin lymphoma during pregnancy].
  • The coexistence of Non Hodgkin Lymphoma and pregnancy has been rarely reported.
  • We are describing the case of 26-year-old pregnant woman, to whom two chemotherapy courses were administered because of the lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Pregnancy. Remission Induction. Transplantation, Autologous


35. Gross TG, Termuhlen AM: Pediatric non-Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):167-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually.
  • NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes.
  • This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Curr Oncol Rep. 2007 Nov;9(6):459-65 [17991353.001]
  • (PMID = 20425462.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mounier N, Fermé C: [Particularities of Hodgkin's lymphoma]. Rev Prat; 2010 Jan 20;60(1):75-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Particularities of Hodgkin's lymphoma].
  • [Transliterated title] Particularités du lymphome de Hodgkin.
  • A risk-adapted strategy for adult patients with Hodgkin's lymphoma is based on risk factors at diagnosis.
  • First line chemotherapy with the gold standard ABVD regimen, with 3 or 4 courses for patients without or with risk factors, respectively, followed by radiation therapy targeting the initially affected areas (involved-field RT), at a dose of 30 Gy, is the treatment of choice for all early-stage supradiaphragmatic disease.
  • Treatment for disseminated disease is based on chemotherapy alone.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222316.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


37. Grulich AE, Vajdic CM: The epidemiology of non-Hodgkin lymphoma. Pathology; 2005 Dec;37(6):409-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) includes a group of more than 20 different malignant lymphoproliferative diseases that originate from lymphocytes.
  • These include immune-deficiency-associated central nervous system NHL (Epstein-Barr virus); gastric mucosa-associated lymphoid tissue NHL (Helicobacter pylori); adult T-cell leukemia/lymphoma (human T-lymphotrophic virus type 1) and body cavity-based lymphoma (human herpesvirus 8).
  • Specific autoimmune conditions, including rheumatoid arthritis, systemic lupus erythema, Sjogren's syndrome, psoriasis and coeliac disease are associated with moderately increased risk of NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373224.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 147
  •  go-up   go-down


38. Dalton SO, Poulsen AH, Nørgaard M, McLaughlin JK, Johansen C, Friis S: Tricyclic antidepressants and non-Hodgkin lymphoma. Epidemiology; 2008 Jul;19(4):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tricyclic antidepressants and non-Hodgkin lymphoma.
  • BACKGROUND: An increased risk of non-Hodgkin lymphoma (NHL) has been reported among long-term users of tricyclic antidepressants.
  • CONCLUSIONS: Our results indicate an increased risk of non-Hodgkin lymphoma specifically among long-term users of tricyclic antidepressant medications.
  • [MeSH-major] Antidepressive Agents, Tricyclic / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Denmark / epidemiology. Humans. Incidence. Poisson Distribution. Registries. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552589.001).
  • [ISSN] 1531-5487
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic
  •  go-up   go-down


39. Spinelli JJ, Ng CH, Weber JP, Connors JM, Gascoyne RD, Lai AS, Brooks-Wilson AR, Le ND, Berry BR, Gallagher RP: Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer; 2007 Dec 15;121(12):2767-75
Hazardous Substances Data Bank. OXYCHLORDANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorines and risk of non-Hodgkin lymphoma.
  • Organochlorine chemicals and polychlorinated biphenyls (PCBs) have been suspected as possible risk factors for non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Environmental Exposure / adverse effects. Environmental Pollutants / blood. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / epidemiology. Pesticides / blood. Polychlorinated Biphenyls / blood
  • [MeSH-minor] Adult. Aged. British Columbia / epidemiology. Case-Control Studies. Chlordan / analogs & derivatives. Chlordan / blood. Female. Humans. Hydrocarbons, Chlorinated / blood. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Registries. Risk Assessment. Risk Factors. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17722095.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides; 12789-03-6 / Chlordan; 27304-13-8 / oxychlordane; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


40. Fuchs M, Eichenauer DA, Nogová L, Diehl V, Engert A, German Hodgkin Study Group: Nodular lymphocyte-predominant Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Jul;3(3):126-31
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte-predominant Hodgkin lymphoma.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation.
  • Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of choice for stage IA NLPHL.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Recurrence. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425457.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


41. Miltényi Z, Székely G, Simon Z, Keresztes K, Illés A: [Differences of arteria carotis in patients with Hodgkin's lymphoma]. Magy Onkol; 2005;49(4):343-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differences of arteria carotis in patients with Hodgkin's lymphoma].
  • [Transliterated title] Arteria carotis-eltérések kezelt Hodgkin-lymphomás betegek között.
  • We examined arteria carotis atherosclerosis and stenosis in Hodgkin's lymphoma patients.
  • We examined arteria carotis of 120 Hodgkin's lymphoma patients who have been in complete remission for at least 5 years.
  • Carotis stenosis does not seem to play a role in late mortality in Hodgkin's lymphoma, but if the patient has an increased risk for atherosclerotic changes, then regular examinations are necessary, and other risk factors (smoking, hypertension, diabetes mellitus, hypothyroidism, early menopause) need to be treated.
  • [MeSH-major] Carotid Arteries / pathology. Carotid Stenosis / pathology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518480.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


42. Oshikawa G, Arai A, Sasaki K, Ichinohasama R, Miura O: [Primary multifocal osseous Hodgkin lymphoma]. Rinsho Ketsueki; 2009 Feb;50(2):92-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary multifocal osseous Hodgkin lymphoma].
  • Core needle biopsy of the sternal tumor was performed and a diagnosis of Hodgkin lymphoma (HL) (mixed cellularity) was made.
  • Neither bone marrow biopsy nor cerebrospinal fluid examination showed infiltration of lymphoma cells.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Positron-Emission Tomography. Remission Induction. Tomography, X-Ray Computed. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265301.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 15
  •  go-up   go-down


43. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol; 2009 Jan;144(1):24-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
  • Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15-19 year age group.
  • Hodgkin lymphoma (HL) accounts for the majority (two-thirds) of cases, while the remainder of patients have one of four subtypes of non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL).
  • Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma.
  • This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Humans. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087093.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 115
  •  go-up   go-down


44. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P: Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood; 2008 Dec 15;112(13):5150-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic heterogeneity among non-Hodgkin lymphoma subtypes.
  • Understanding patterns of etiologic commonality and heterogeneity for non-Hodgkin lymphomas may illuminate lymphomagenesis.
  • We present the first systematic comparison of risks by lymphoma subtype for a broad range of putative risk factors in a population-based case-control study, including diffuse large B-cell (DLBCL; N = 416), follicular (N = 318), and marginal zone lymphomas (N = 106), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).
  • Autoimmune conditions increased risk for marginal zone lymphoma alone.
  • The tumor necrosis factor G-308A polymorphism (rs1800629) increased risks for both DLBCL and marginal zone lymphoma.
  • We observed no significant risk factors for follicular lymphoma alone.
  • These data clearly support both etiologic commonality and heterogeneity for lymphoma subtypes, suggesting that immune dysfunction is of greater etiologic importance for DLBCL and marginal zone lymphoma than for CLL/SLL and follicular lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):953-64 [16221809.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):293-7 [16113054.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):516-25 [15951670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):251-7 [16492912.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):47-55 [16731576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1281-6 [16835324.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1287-94 [16835325.001]
  • [Cites] Pharmacogenet Genomics. 2006 Aug;16(8):537-45 [16847422.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3161-7 [16857995.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2477-87 [17169793.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):268-74 [17270016.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):652-9 [17204518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):159-68 [11936822.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S42-5 [12142961.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):694-704 [12209158.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):148-54 [14718216.001]
  • [Cites] Genes Immun. 2004 Aug;5(5):315-29 [14973548.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Mutat Res. 1975 Dec;31(6):347-64 [768755.001]
  • [Cites] Carcinogenesis. 1987 May;8(5):665-8 [3581424.001]
  • [Cites] Jpn J Cancer Res. 1989 Dec;80(12):1176-8 [2516847.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):295-301 [1497384.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2221-7 [8895492.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):545-51 [10223180.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1951-8 [10371587.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3050-9 [17119116.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1365-72 [17481729.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1180-5 [17666372.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):888-94 [18506687.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1203-14 [16215871.001]
  • (PMID = 18796628.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / PC / N02-PC-71105; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / PC / N01-PC-67009; None / None / / N01 PC065064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2597610
  •  go-up   go-down


45. Linet MS, Taggart T, Severson RK, Cerhan JR, Cozen W, Hartge P, Colt J: Cellular telephones and non-Hodgkin lymphoma. Int J Cancer; 2006 Nov 15;119(10):2382-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular telephones and non-Hodgkin lymphoma.
  • Dramatic increase in hand-held cellular telephone use since the 1980s and excess risk of lymphoproliferative malignancies associated with radio-frequency radiation (RFR) exposures in epidemiological and experimental studies motivated assessment of cellular telephones within a comprehensive US case-control investigation of non-Hodgkin lymphoma (NHL).
  • Little evidence linked use of cellular telephones with total, diffuse large B-cell lymphoma or follicular NHL.
  • [MeSH-major] Cell Phones. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Middle Aged. Odds Ratio. Sex Distribution. Surveys and Questionnaires. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894556.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N02-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


46. Colt JS, Severson RK, Lubin J, Rothman N, Camann D, Davis S, Cerhan JR, Cozen W, Hartge P: Organochlorines in carpet dust and non-Hodgkin lymphoma. Epidemiology; 2005 Jul;16(4):516-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorines in carpet dust and non-Hodgkin lymphoma.
  • BACKGROUND: The incidence of non-Hodgkin lymphoma (NHL) has risen over the past several decades.
  • [MeSH-major] Dust. Environmental Exposure / adverse effects. Environmental Pollutants / toxicity. Floors and Floorcoverings. Hydrocarbons, Chlorinated / toxicity. Lymphoma, Non-Hodgkin / chemically induced
  • [MeSH-minor] Adult. Aged. Case-Control Studies. European Continental Ancestry Group. Female. Humans. Male. Middle Aged. Pesticides / toxicity. Regression Analysis. SEER Program. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951670.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67008; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / CP / N02-CP-19114; United States / NCI NIH HHS / CP / N02-CP-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dust; 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides
  •  go-up   go-down


47. Werbrouck B, Meire V, De Bleecker JL: Multiple neurological syndromes during Hodgkin lymphoma remission. Acta Neurol Belg; 2005 Mar;105(1):48-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple neurological syndromes during Hodgkin lymphoma remission.
  • We report a young patient who developed a stiff man syndrome (SMS) long after remission of Hodgkin lymphoma.
  • This patient is remarkable because he has had several other potentially autoimmune or paraneoplastic neurological syndromes including limbic encephalitis and demyelinating polyneuropathy which also occurred years after remission from Hodgkin disease.
  • [MeSH-major] Hodgkin Disease / complications. Paraneoplastic Syndromes, Nervous System / etiology. Stiff-Person Syndrome / etiology
  • [MeSH-minor] Adult. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861997.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


48. Hua MT, Blaise P, De Leval L, Rakic JM: Frosted branch angiitis with undiagnosed Hodgkin lymphoma. Eur J Ophthalmol; 2009 Mar-Apr;19(2):310-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frosted branch angiitis with undiagnosed Hodgkin lymphoma.
  • PURPOSE: To report the case of a patient with bilateral frosted branch angiitis and undiagnosed Hodgkin lymphoma.
  • A supraclavicular lymph node biopsy led to the diagnosis of nodular sclerosis Hodgkin lymphoma.
  • CONCLUSIONS: The occurrence of frosted branch angiitis in combination with classical Hodgkin lymphoma, although possibly coincidental, raises the possibility of a paraneoplastic syndrome.
  • Thus, we suggest that, for patients with frosted branch angiitis, Hodgkin lymphoma should be considered in the diagnostic workup.
  • [MeSH-major] Hodgkin Disease / diagnosis. Retinal Vasculitis / diagnosis
  • [MeSH-minor] Administration, Oral. Biopsy. Fluorescein Angiography. Glucocorticoids / therapeutic use. Humans. Infusions, Intravenous. Lymph Nodes / pathology. Male. Methylprednisolone / therapeutic use. Visual Acuity. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253256.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


49. Setty BA, Termuhlen AM: Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep; 2010 Jul;5(3):163-8
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pediatric non-hodgkin lymphoma.
  • Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults.
  • Understanding of these rare types of NHL comes from small pediatric case series or the adult literature.
  • Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Child. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20490722.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


50. Feltl D, Markova J, Mocikova H, Dedeckova K, Kozak T: Prognostic impact of bone involvement in Hodgkin lymphoma. Neoplasma; 2008;55(2):96-100
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of bone involvement in Hodgkin lymphoma.
  • The purpose of the study is to determine incidence and prognostic impact of osseous Hodgkin lymphoma (HL).
  • All patients were treated according to protocols of the German Hodgkin Study Group (GHSG).
  • We recorded 14 cases of osseous HL (7 %), always with concurrent nodal disease.
  • [MeSH-major] Bone Neoplasms / mortality. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18237246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


51. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


52. Melbye M, Smedby KE, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, Schöllkopf C, Sundström C, Chang ET, Koskela P, Adami HO, Hjalgrim H: Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst; 2007 Jan 17;99(2):158-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atopy and risk of non-Hodgkin lymphoma.
  • BACKGROUND: A possible connection between allergy and cancer has been suspected, but allergy-related conditions or atopy have been inconsistently associated with reduced risks of non-Hodgkin lymphoma.
  • METHODS: We carried out a population-based study of 3055 case patients with non-Hodgkin lymphoma and 3187 control subjects in Denmark and Sweden, including questionnaire information on allergy and blood specimens, and a nested case-control study within a prospective cohort of more than 400,000 Finnish women.
  • In the second study, serum specimens from the 198 case patients who developed non-Hodgkin lymphoma within a median of 8.9 years after the blood was drawn were matched with serum specimens from 594 control subjects.
  • Dissemination of disease was classified by the Ann Arbor system.
  • RESULTS: In the first study, ever having hay fever, but not other allergic conditions, was associated with a reduced risk of non-Hodgkin lymphoma.
  • In particular, subjects with specific IgE reactivity in serum had a 32% (95% CI = 20% to 42%) lower risk of overall non-Hodgkin lymphoma than those without such reactivity.
  • However, among case patients, dissemination of the disease was strongly inversely associated with specific IgE reactivity.
  • In the second (i.e., prospective) study, no association was found between non-Hodgkin lymphoma and specific IgE reactivity, except possibly immediately before a diagnosis of non-Hodgkin lymphoma (> or = 10 years before diagnosis, OR = 1.00, 95% CI = 0.48 to 2.09; 5-9 years before, OR = 0.95, 95% CI = 0.50 to 1.84; 1-4 years before, OR = 0.33, 95% CI = 0.11 to 1.02; and < 1 year before, OR = 0.27, 95% CI = 0.03 to 2.31).
  • CONCLUSION: Allergy may not be causally associated with the risk of non-Hodgkin lymphoma.
  • The inverse association observed in some case-control studies may arise because non-Hodgkin lymphoma suppresses the immunologic response to allergens.
  • [MeSH-major] Hypersensitivity, Immediate / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Denmark / epidemiology. Female. Finland / epidemiology. Humans. Immunoglobulin E / immunology. Logistic Models. Male. Middle Aged. Odds Ratio. Prospective Studies. Retrospective Studies. Rhinitis, Allergic, Perennial / complications. Risk Assessment. Risk Factors. Selection Bias. Surveys and Questionnaires. Sweden / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Sep 19;99(18):1417 [17848674.001]
  • (PMID = 17227999.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R03 CA 101496-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


53. Paes FM, Kalkanis DG, Sideras PA, Serafini AN: FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics; 2010 Jan;30(1):269-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
  • The term extranodal disease refers to lymphomatous infiltration of anatomic sites other than the lymph nodes.
  • Almost any organ can be affected by lymphoma, with the most common extranodal sites of involvement being the stomach, spleen, Waldeyer ring, central nervous system, lung, bone, and skin.
  • The prevalence of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease has increased in the past decade.
  • More recently, hybrid PET/CT has become the standard imaging modality for initial staging, follow-up, and treatment response assessment in patients with lymphoma and has proved superior to CT in these settings.
  • Certain PET/CT patterns are suggestive of extranodal disease and can help differentiate tumor from normal physiologic FDG activity, particularly in the mucosal tissues, bone marrow, and organs of the gastrointestinal tract.
  • In addition, a knowledge of the differences in FDG avidity among the histologic subtypes of lymphoma, appropriate timing of scanning after therapeutic interventions, and use of techniques to prevent brown fat uptake are essential for providing the oncologist with accurate information.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Subtraction Technique. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083598.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


54. Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF: Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer; 2005 Sep 10;116(4):646-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma.
  • Somatic inactivation of NFKBIA, the gene encoding IkappaBalpha, is a frequent occurrence in the malignant Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL).
  • [MeSH-major] Genetic Predisposition to Disease. Germ-Line Mutation. Hodgkin Disease / genetics. I-kappa B Proteins / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. DNA Mutational Analysis. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Molecular Sequence Data. Pedigree. Polymorphism, Genetic. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15858823.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins
  •  go-up   go-down


55. Herbertson RA, Evans LS, Hutchinson J, Horsman J, Hancock BW: Poor outcome in adolescents with high-risk Hodgkin lymphoma. Int J Oncol; 2008 Jul;33(1):145-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome in adolescents with high-risk Hodgkin lymphoma.
  • This retrospective study looks at the differences between adolescents (15-19 years) and young adults (20-25 years), diagnosed with Hodgkin lymphoma and treated at the same adult institution.
  • Outcome according to risk category was evaluated, and although there were no significant differences in the whole cohort, or low and intermediate-risk categories, high-risk adolescent patients had a significantly worse outcome compared to that of young adults.
  • In these high-risk patients, 5-year event free survival was 43.6% in adolescents compared to 58.7% in young adults (log-rank survival p=0.03), and the 5-year overall survival in adolescents was 66.7% compared to 84.4% in the young adults (p=0.04).
  • The difference could not be explained in terms of differences in histological subtype (p=0.5), proportion of patients with bulky (p=0.6) or extranodal disease (p=0.6), initial treatment received (chemotherapy alone compared to combination therapy, p=0.2), or proportion proceeding to high-dose treatment after initial treatment failure (p=0.6).
  • A significantly greater proportion of high-risk adolescents had primary progressive disease (PPD) [eight high-risk adolescents (33.3%) compared to two high-risk young adults (7.7%), p=0.02].
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Humans. Retrospective Studies. Risk

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575760.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


56. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP: Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant; 2008 Apr;14(4):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
  • Allogeneic stem cell transplantation (SCT) with reduced-intensity conditioning (RIC) has the potential to lead to long-term remissions for patients with lymphoma.
  • However, the role of RIC SCT in the treatment of lymphoma is still unclear.
  • Specifically, the relative benefit of RIC SCT across lymphoma histologies and the prognostic factors in this population are incompletely defined.
  • We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan.
  • Thirty-six patients had Hodgkin disease (HD) and 51 had non-Hodgkin lymphoma (NHL).
  • Three-year overall survival (OS) was 56% for patients with HD, 81% for indolent NHL, 42% for aggressive NHL, and 40% for mantle cell lymphoma.
  • These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2342-50 [8246023.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1291-6 [8648386.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):943-51 [15806128.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):655-61 [16007106.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):235-44 [16513231.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64 [17084369.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4314-21 [11731514.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • (PMID = 18342784.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NHLBI NIH HHS / HL / HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NHLBI NIH HHS / HL / HL070149-05; United States / NHLBI NIH HHS / HL / P01 HL070149-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS43829; NLM/ PMC2364453
  •  go-up   go-down


57. Díez L, Guijarro IG, Vaamonde P, Fernández P: [Primary manifestation of Hodgkin lymphoma in adenoid. About a case]. Acta Otorrinolaringol Esp; 2010 Nov-Dec;61(6):462-4
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary manifestation of Hodgkin lymphoma in adenoid. About a case].
  • [Transliterated title] Manifestación primaria de linfoma de Hodgkin en adenoides. A propósito de un caso.
  • Hodgkin's disease (HD) accounts for only 10-35% of all cases, where the lymph node is affected in 70-80%.
  • We present the case of a patient with HD with extranodal involvement, given the rarity of this entity.
  • [MeSH-major] Adenoids. Hodgkin Disease / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Adenoids.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20092806.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


58. Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons A, Balagué O, Gel B, Abrisqueta P, Lopez-Guillermo A, Artells R, Montserrat E, Monzo M: MicroRNA expression profiling in classic Hodgkin lymphoma. Blood; 2008 Mar 1;111(5):2825-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiling in classic Hodgkin lymphoma.
  • We analyzed miRNA expression in classic Hodgkin lymphoma (cHL) and the influence of Epstein-Barr virus (EBV) infection on the miRNA expression profiles.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Herpesvirus 4, Human / physiology. Humans. In Situ Hybridization. Lymph Nodes / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089852.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


59. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC: Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol; 2010 Dec;28(4):168-79
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preservation after chemotherapy for Hodgkin lymphoma.
  • Treatment for Hodgkin lymphoma can negatively affect fertility.
  • This review summarizes data on fertility after chemotherapy in adult patients.
  • For females with a partner, IVF followed by embryo cryopreservation is a widely available method, but this necessitates postponement of lymphoma therapy for at least a month.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Azoospermia / chemically induced. Cryopreservation / methods. Female. Humans. Male. Ovarian Diseases / chemically induced

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [CommentIn] Hematol Oncol. 2011 Mar;29(1):52; author reply 53 [20535782.001]
  • (PMID = 20232475.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


60. Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami HO, Glimelius B, Hjalgrim H, Melbye M: Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma. Int J Cancer; 2009 Jun 1;124(11):2616-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.
  • Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL.
  • Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD80 / blood. Female. Humans. Immunoglobulin E / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235925.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


61. Willett EV, Roman E: Obesity and the risk of Hodgkin lymphoma (United Kingdom). Cancer Causes Control; 2006 Oct;17(8):1103-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and the risk of Hodgkin lymphoma (United Kingdom).
  • OBJECTIVE: The aim of the study was to investigate the relationship between Hodgkin lymphoma (HL) and obesity.
  • METHODS: A population-based case-control study recruited incident cases of lymphoma in England during 1998-2003.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Risk Factors


62. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr: Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst; 2006 Jul 5;98(13):936-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly increasing incidence of ocular non-hodgkin lymphoma.
  • A recent report suggesting that ocular adnexal non-Hodgkin lymphoma (NHL) may be related to Chlamydia psittaci infection underscores the need for reliable epidemiologic data for this malignancy.
  • [MeSH-major] Eye Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Chlamydophila psittaci. Female. Humans. Incidence. Lymphoma, B-Cell, Marginal Zone / epidemiology. Male. Middle Aged. Psittacosis / complications. Psittacosis / microbiology. SEER Program. Sex Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818858.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


63. Scotti SD, Laudadio J: Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET. J Radiol Case Rep; 2009;3(8):18-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.
  • Testicular relapse of leukemia and lymphoma is a well-recognized phenomenon, with testicular relapse of lymphoma being more common in the adult population and leukemia relapse being more common in the pediatric population.
  • With the advent of F-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the evaluation of lymphoma it is possible to evaluate testicular uptake of FDG and to detect primary testicular lymphoma or testicular relapse on the FDG-PET examination.
  • Testicular relapse of non-Hodgkin lymphoma (NHL) detected on FDG-PET has been reported previously.
  • Elevated activity or lateralizing activity should be viewed with suspicion, with etiologies including primary testicular tumor, primary or secondary testicular lymphoma and metastatic disease with other etiologies less likely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vivo. 1991 May-Jun;5(3):297-9 [1893083.001]
  • [Cites] Lancet Oncol. 2002 Jun;3(6):357-63 [12107023.001]
  • [Cites] Cancer. 1969 Jun;23(6):1290-5 [5818886.001]
  • (PMID = 22470678.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303329
  • [Keywords] NOTNLM ; Non-Hodgkin’s Lymphoma / PET / PET/CT / testicular lymphoma
  •  go-up   go-down


64. Engels EA: Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):401-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious agents as causes of non-Hodgkin lymphoma.
  • Among exposures presently viewed as possible etiologic factors in non-Hodgkin lymphoma (NHL), infections are close to being regarded as established causes.
  • Lymphocyte-transforming viruses include Epstein Barr virus (linked to Burkitt's lymphoma, NHLs in immunosuppressed individuals, and extranodal natural killer/T-cell NHL), human herpesvirus 8 (primary effusion lymphoma), and human T lymphotropic virus type I (adult T-cell leukemia/lymphoma).
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337646.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


65. Bartlett NL: Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program; 2005;:245-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
  • Autologous stem cell transplant remains the standard of care for relapsed Hodgkin lymphoma (HL).
  • For patients with chemo-refractory disease at relapse and those failing autologous transplant, the long-term prognosis remains poor.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304388.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


66. Hartge P, Colt JS, Severson RK, Cerhan JR, Cozen W, Camann D, Zahm SH, Davis S: Residential herbicide use and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):934-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential herbicide use and risk of non-Hodgkin lymphoma.
  • CONTEXT: Environmental exposure to herbicides has been hypothesized to contribute to the long-term increase in non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Environmental Exposure / adverse effects. Herbicides / adverse effects. Lymphoma, Non-Hodgkin / chemically induced. Population Surveillance / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Dust / analysis. Female. Housing. Humans. Male. Middle Aged. Multicenter Studies as Topic. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824166.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dust; 0 / Herbicides
  • [Number-of-references] 22
  •  go-up   go-down


67. Broderick P, Cunningham D, Vijayakrishnan J, Cooke R, Ashworth A, Swerdlow A, Houlston R: IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol; 2010 Feb;148(3):413-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.
  • The reciprocal familial risk between chronic lymphocytic leukaemia (CLL) and Hodgkin lymphoma (HL) suggests genetic variants with pleiotropic effects may influence the risk of both CLL and HL.
  • [MeSH-major] Hodgkin Disease / genetics. Interferon Regulatory Factors / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA, Neoplasm / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Risk Assessment / methods. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804451.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interferon Regulatory Factors; 0 / Neoplasm Proteins; 0 / interferon regulatory factor-4
  •  go-up   go-down


68. Hodgson DC, Hudson MM, Constine LS: Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol; 2007 Jul;17(3):230-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity.
  • Historically, both adult and childhood Hodgkin lymphoma (HL) were treated with full-dose (35-45 Gy) extended-field radiation therapy (RT).
  • Although this treatment was the first to produce reliable disease control, the resulting late toxicity led pediatric oncologists to pioneer the use of combined chemotherapy and low-dose (15-25 Gy) involved-field RT for all stages of HL.
  • Currently, standard treatment of childhood HL is risk adapted; those with favorable risk disease typically receive 2 to 4 cycles of multi-agent chemotherapy with low-dose IFRT, whereas those with higher-risk disease receive more intensive chemotherapy before IFRT.
  • In contrast to adult HL, IFRT remains an important component of the treatment of advanced-stage HL in pediatric patients.
  • The challenge is to refine therapy in a rare disease in which long-time intervals are necessary to observe an adequate number of events (treatment failure or late effects) to answer judicious questions.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Humans. Neoadjuvant Therapy. Neoplasm Staging. Patient Care Planning. Prognosis. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591570.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 100
  •  go-up   go-down


69. Centkowski P, Brydak L, Machała M, Kalinka-Warzocha E, Błasińska-Morawiec M, Federowicz I, Walewski J, Wegrzyn J, Wołowiec D, Lech-Marańda E, Sawczuk-Chabin J, Biliński P, Warzocha K, Polish Lymphoma Research Group: Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol; 2007 May;27(3):339-46
MedlinePlus Health Information. consumer health - Flu Shot.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma.
  • PURPOSE: The purpose of this study was to assess humoral response to influenza vaccine in patients (pts) with non-Hodgkin lymphoma (NHL) as compared to healthy subjects (ctrl).
  • [MeSH-major] Influenza Vaccines / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies / blood. Antibodies / immunology. Female. Hemagglutinins / immunology. Humans. Influenza A virus / immunology. Influenza, Human / immunology. Influenza, Human / prevention & control. Male. Middle Aged. Neuraminidase / immunology. Neuraminidase / metabolism. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345151.001).
  • [ISSN] 0271-9142
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Hemagglutinins; 0 / Influenza Vaccines; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


70. Cabrera ME, García H, Lois V, León A, Peña K, Rossle A, Cerda B, Rojas H, Meneses P, Merino C, Aspillaga A, Vittini de C, Oliva J, Hales C, Rosas J, Programa Nacional de Cáncer del Adulto, Ministerio de Salud: [Hodgkin lymphoma in Chile: experience of the national adult cancer program]. Rev Med Chil; 2007 Mar;135(3):341-50
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
  • [Transliterated title] Linfoma de Hodkin en Chile: experiencia de 15 años del Programa Nacional de Cáncer del Adulto.
  • BACKGROUND: Hodgkin lymphoma is a highly curable disease.
  • AIM: To evaluate the clinical characteristics and the treatment results of Hodgkin lymphoma patients of the National Cancer Program in Chile.
  • PATIENTS AND METHODS: Prospective assessment of 682 patients treated in 18 adult cancer centers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. National Health Programs
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chi-Square Distribution. Chile. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505580.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] Chile
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; ABVD protocol; CMOPP protocol; NOVP protocol
  • [Investigator] Hales C; López H; Zambrano V; Blanchard N; Vacarezza R; Merino C; Toro I; Meneses P; Rojas B; Aspillaga A; Fahrenkrog A; Rossle A; Bancalari G; Fernández A; García C; Schorwer M; Pérez C; Oliva J; Vittini de R C; Yáñez E; Peña A; Rodríguez C; León A; Pilleux L; Calderón S; Salas P; Lesina B; Zapata C; Cardemil B; Zumelzu N; Silva M; Rosas J; González ML; Liberón B; Cerda B; Klivadenko W; Sola A; Cao C; Peña K; Puente L; Bronfman L; Torrens M; Gutiérrez J; Cabrera ME; Undurraga MS; Gray AM; Puga B; Guerra C; Vacarezza R; Etcheverrry R; Ducach G; García H; Riquelme AM; Corvalán H; Lois V; Con I; Muñoz L; Bustos MI; Castro JL; Liendo F; Osorio G; Araos D; Anguita T; Rojas H; Suárez D
  •  go-up   go-down


71. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L: Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol; 2006 Sep;24(3):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.
  • This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL).
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiography. Positron-Emission Tomography
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18 / administration & dosage. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymph Nodes / radiography. Male. Middle Aged. Radiopharmaceuticals / administration & dosage. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 John Wiley & Sons, Ltd.
  • (PMID = 16729353.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Steiropoulos P, Kouliatsis G, Karpathiou G, Popidou M, Froudarakis ME: Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas. Respiration; 2009;77(4):459-63
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas.
  • Primary pleural lymphoma is rare.
  • It occurs in only 7% of lymphoma cases.
  • We report herein two cases of primary pleural Hodgkin and non-Hodgkin follicular lymphomas diagnosed by thoracoscopy under local anesthesia.
  • The pleural findings during thoracoscopy differed in the two cases and selective pleural biopsies under optical forceps led to the diagnosis of lymphoma.
  • To date, primary pleural Hodgkin and non-Hodgkin follicular lymphomas have not been reported.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Follicular / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Dyspnea / etiology. Female. Humans. Male. Middle Aged. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18503251.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


73. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood; 2006 Dec 1;108(12):3786-91
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.
  • In persons with HIV/AIDS (PWHAs), Hodgkin lymphoma (HL) risk is increased.


74. Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A: Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma; 2009 Nov;50(11):1803-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
  • The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease.
  • After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aspergillosis / chemically induced. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Pericarditis / chemically induced. Peripheral Blood Stem Cell Transplantation. Pneumonia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Recurrence. Retrospective Studies. Shock, Septic / chemically induced. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Nov;50(11):1733-4 [19883301.001]
  • (PMID = 19860621.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


75. De Roos AJ, Davis S, Colt JS, Blair A, Airola M, Severson RK, Cozen W, Cerhan JR, Hartge P, Nuckols JR, Ward MH: Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma. Environ Res; 2010 Jan;110(1):70-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential proximity to industrial facilities and risk of non-Hodgkin lymphoma.
  • Industrial pollution has been suspected as a cause of non-Hodgkin lymphoma (NHL), based on associations with chemical exposures in occupational studies.
  • Increased risk of NHL was observed in relation to lumber and wood products facilities (SIC 24) for the shortest distance of residential proximity (< or =0.5 mile: odds ratio [OR]=2.2, 95% confidence interval [CI]: 0.4-11.8) or the longest duration (10 years: OR=1.9, 95% CI: 0.8-4.8); the association with lumber facilities was more apparent for diffuse large B-cell lymphoma (lived within 2 miles: OR=1.7, 95% CI: 1.0-3.0) than for follicular lymphoma (OR=1.1, 95% CI: 0.5-2.2).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Epidemiology. 2003 Nov;14(6):687-93 [14569184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1981 Feb;25:49-197 [6939657.001]
  • [Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):542-7 [15951673.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Occup Environ Med. 2009 Jan;66(1):23-31 [18805886.001]
  • [Cites] BMC Public Health. 2009;9:26 [19159450.001]
  • (PMID = 19840879.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / R03 CA115183; United States / NCI NIH HHS / CA / CA115183-02; United States / NCI NIH HHS / CA / R03 CA115183-02; None / None / / N01 PC065064; United States / NCI NIH HHS / CA / R03CA115183
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Industrial Waste
  • [Other-IDs] NLM/ NIHMS153621; NLM/ PMC2795078
  •  go-up   go-down


76. Illés A, Simon Z, Tóth E, Rosta A, Miltényi Z, Molnár Z: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres. Pathol Oncol Res; 2008 Dec;14(4):411-21
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
  • Clinicopathological features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) differ from those of the classical Hodgkin lymphoma (cHL).
  • We analyzed the clinical features, treatment and survival data of 536 Hodgkin lymphoma patients who had been diagnosed and primarily treated in our institutes between 1995 and 2004.
  • Sixteen (3%) of the patients were diagnosed with NLPHL, 93% of them presented with early-stage disease.
  • None of the patients showed extranodal or splenic involvement or bulky disease.
  • Two NLPHL cases transformed to non-Hodgkin's lymphoma.
  • CONCLUSIONS: NLPHL is a rare disease, thus these are limited experiences with its diagnosis and treatment.
  • Since the disease has an excellent outcome, it is very important to prefer less toxic or local therapies to reach long term survival similar to that of the normal population.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / mortality. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hungary. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431694.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA, McDuffie HH: Ethnicity and incidence of Hodgkin lymphoma in Canadian population. BMC Cancer; 2009;9:141
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and incidence of Hodgkin lymphoma in Canadian population.
  • BACKGROUND: Research has shown that ethnicity is a significant predictor of Hodgkin lymphoma (HL).
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / ethnology
  • [MeSH-minor] Adult. Aged. Canada / epidemiology. Case-Control Studies. Environmental Exposure. Ethnic Groups. Female. Humans. Incidence. Male. Medical History Taking. Middle Aged. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Environ Med. 2005 Aug;47(8):806-16 [16093930.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1441-7 [15941953.001]
  • [Cites] BMC Public Health. 2008;8:152 [18462495.001]
  • [Cites] BMC Cancer. 2009;9:70 [19250521.001]
  • [Cites] J Epidemiol Community Health. 2000 Jun;54(6):431-6 [10818118.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Leuk Res. 2002 Mar;26(3):261-9 [11792415.001]
  • [Cites] Occup Environ Med. 2003 Oct;60(10):798-801 [14504372.001]
  • [Cites] Hematol Oncol. 2004 Mar;22(1):11-26 [15152367.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):572-9 [15226778.001]
  • [Cites] J Lancet. 1966 Jan;86(1):5-11 [5900921.001]
  • [Cites] Br J Cancer. 1966 Sep;20(3):434-7 [5922249.001]
  • [Cites] Scott Med J. 1969 Feb;14(2):51-4 [5812963.001]
  • [Cites] Lancet. 1973 Apr 21;1(7808):884-5 [4123430.001]
  • [Cites] Nature. 1974 Oct 4;251(5474):441-2 [4421071.001]
  • [Cites] Cancer Res. 1980 Jan;40(1):1-12 [7349888.001]
  • [Cites] Br J Cancer. 1981 Feb;43(2):169-76 [7470379.001]
  • [Cites] Br J Cancer. 1983 Aug;48(2):217-25 [6882662.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):66-74 [4014202.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):235-9 [3456062.001]
  • [Cites] JAMA. 1986 Sep 5;256(9):1141-7 [3801091.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1986;41:1-407 [3473020.001]
  • [Cites] Br J Cancer. 1987 Oct;56(4):505-8 [3689667.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):19-24 [3342183.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Scand J Work Environ Health. 1988 Aug;14(4):224-30 [3175554.001]
  • [Cites] Clin Invest Med. 1990 Dec;13(6):333-8 [2078912.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):543-8 [1654982.001]
  • [Cites] Can J Public Health. 1992 Jan-Feb;83(1):31-3 [1571879.001]
  • [Cites] Cancer Causes Control. 1992 Sep;3(5):449-56 [1525326.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1991;53:5-586 [1688189.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):602-6 [8319194.001]
  • [Cites] BMJ. 1994 Jul 30;309(6950):327-30 [8086873.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):461-2 [7824019.001]
  • [Cites] Cancer Causes Control. 1996 May;7(3):312-21 [8734824.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Histopathology. 1997 Mar;30(3):227-33 [9088951.001]
  • [Cites] Am J Public Health. 1998 Sep;88(9):1303-7 [9736867.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1282-8 [18323551.001]
  • (PMID = 19432977.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2690601
  •  go-up   go-down


78. Engels EA, Rollison DE, Hartge P, Baris D, Cerhan JR, Severson RK, Cozen W, Davis S, Biggar RJ, Goedert JJ, Viscidi RP: Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer; 2005 Dec 20;117(6):1013-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma.
  • Because JCV can infect lymphocytes and cause chromosomal damage, it is a plausible candidate to cause non-Hodgkin lymphoma (NHL).
  • Because no deficit of BKV antibody was seen in NHL cases, and because antibody levels did not change materially with chemotherapy, we suggest that the lower levels of JCV antibody observed in NHL patients may not be due entirely to a disease or treatment effect.
  • [MeSH-major] Antibodies, Viral / blood. BK Virus / immunology. JC Virus / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. DNA, Viral / urine. Female. HIV Infections / virology. Homosexuality. Humans. Immunoglobulin G / blood. Male. Middle Aged. National Institutes of Health (U.S.). Polymerase Chain Reaction. Registries. SEER Program. United States. Virus Replication. Virus Shedding

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986438.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Immunoglobulin G
  •  go-up   go-down


79. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, Davis S, Severson RK, Rothman N, Chanock SJ, Hartge P: Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res; 2007 May 15;67(10):5042-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.
  • Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non-Hodgkin lymphoma (NHL) in a large pooled analysis.
  • We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma].
  • NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (OR(NHL), 2.1; 95% CI, 1.0-4.2) or the IL10 T3575A TA/AA genotype (OR(NHL), 1.6; 95% CI, 0.9-2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Interleukin-10 / genetics. Interleukin-10 / immunology. Male. Middle Aged. Polymorphism, Single Nucleotide. Risk Factors. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510437.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / PC / N01-PC-67008; United States / NCI NIH HHS / PC / N01-PC-67009; United States / NCI NIH HHS / PC / N01-PC-67010; United States / NCI NIH HHS / PC / N01-PC-71105; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


80. Bakshi NA, Finn WG, Schnitzer B, Valdez R, Ross CW: Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. Arch Pathol Lab Med; 2007 May;131(5):742-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
  • Fascin is a sensitive marker for classical Reed-Sternberg cells and has a high negative predictive value for diagnosis of classical Hodgkin lymphoma (CHL).
  • Fascin has been used to distinguish CHL from non-Hodgkin lymphoma.
  • Recently, it was shown that fascin might not help differentiate CHL from anaplastic large cell lymphoma (ALCL).
  • OBJECTIVE: To analyze fascin expression in diffuse large B-cell lymphoma (DLBCL) and also reexamine its usefulness in discriminating CHL from ALCL.
  • Fascin expression was compared across each type of lymphoma with additional correlation between fascin positivity and ALK-1 expression in ALCL performed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carrier Proteins / biosynthesis. Hodgkin Disease / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Microfilament Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity


81. Darby S, Hancock BW: Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience. Int J Oncol; 2005 Apr;26(4):1093-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience.
  • We evaluated clinical features, management and survival of patients with localised (stage 1E or 2E) testicular non-Hodgkin lymphoma (NHL) presenting to the Sheffield Lymphoma Group between 1972 and 2002.
  • Thirty consecutive eligible patients were identified from the lymphoma database and clinical records of all were reviewed.
  • Five (17%) had immediate disease progression following orchidectomy or whilst on treatment.
  • Six (20%) died of causes not related to their lymphoma.
  • Primary testicular lymphoma is an uncommon and poor prognosis disease usually affecting older men.
  • The data and experience available to guide the treatment strategies for testicular lymphoma are limited.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Neoplasm Recurrence, Local. Orchiectomy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies


82. Aguilera NS, Chen J, Bijwaard KE, Director-Myska AE, Barekman CL, Millward C, Lichy J, Abbondanzo SL: Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens. Arch Pathol Lab Med; 2006 Dec;130(12):1772-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens.
  • CONTEXT: Reed-Sternberg cells in classic Hodgkin lymphoma are enigmatic and difficult to study because they are so sparse.
  • Rarely, Reed-Sternberg cells in classic Hodgkin lymphoma express T-cell antigens, suggesting a possible T-cell origin.
  • OBJECTIVE: To determine whether there is a difference in genotype between classic Hodgkin lymphoma and classic Hodgkin lymphoma expressing T-cell antigens and to document T-cell clonality.
  • DESIGN: We studied 4 cases of Hodgkin lymphoma with a characteristic phenotype and immunoreactivity for CD2 and CD3.
  • Comparative genomic hybridization analysis revealed significant overlap in genomic alteration in Hodgkin lymphoma cases regardless of genotype or phenotype and several regions of imbalance specific to CD3+ Hodgkin lymphoma cases.
  • All patients are alive with no evidence of disease from 10 to 44 months.
  • CONCLUSIONS: Our findings suggest that a T-cell phenotype classic Hodgkin lymphoma can be supported by genotypic studies and that there may be cytogenetic differences between classic Hodgkin lymphoma and Hodgkin lymphoma expressing T-cell antigens.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Nucleic Acid Hybridization / methods. Reed-Sternberg Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Clone Cells. Female. Genotype. Humans. Immunohistochemistry. Lasers. Lymph Nodes / pathology. Microdissection

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149949.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Saitoh T, Matsushima T, Yamane A, Sakuraya M, Irisawa H, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Nojima Y, Murakami H: Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes. Acta Haematol; 2007;117(4):238-41
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma accompanied by aplastic anemia and polyclonal expansion of large granular lymphocytes.
  • Immunologic abnormalities have been described in patients with Hodgkin lymphoma, including autoimmune hemolytic anemia and immune thrombocytopenic purpura.
  • The concurrent diagnoses of Hodgkin lymphoma and acquired aplastic anemia, however, is extremely rare.
  • We report a 56-year-old Japanese female patient with severe aplastic anemia and increased large granular lymphocytes prior to the recurrence of Hodgkin lymphoma.
  • After being in remission for 10 years from Hodgkin lymphoma, she developed progressive pancytopenia.
  • No lymphadenopathy was observed that would suggest a relapse of Hodgkin lymphoma.
  • Autopsy revealed the recurrence of Hodgkin lymphoma, nodular sclerosis in the lymph nodes and markedly hypocellular bone marrow.
  • Although autoimmune disorders are described in Hodgkin lymphoma, our case shows a rare instance of a patient who had aplastic anemia as the first manifestation of a relapse of Hodgkin lymphoma.
  • [MeSH-major] Anemia, Aplastic / complications. Hodgkin Disease / complications. Lymphocytes / cytology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Transfusion. Female. Humans. Magnetic Resonance Imaging. Middle Aged


84. Martín-Subero JI, Klapper W, Sotnikova A, Callet-Bauchu E, Harder L, Bastard C, Schmitz R, Grohmann S, Höppner J, Riemke J, Barth TF, Berger F, Bernd HW, Claviez A, Gesk S, Frank GA, Kaplanskaya IB, Möller P, Parwaresch RM, Rüdiger T, Stein H, Küppers R, Hansmann ML, Siebert R, Deutsche Krebshilfe Network Project Molecular Mechanisms in Malignant Lymphomas: Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res; 2006 Nov 1;66(21):10332-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
  • However, despite the predominant B-cell origin of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL), the presence of chromosomal translocations in IG loci has not yet been systematically explored.
  • [MeSH-major] Chromosome Breakage. Genes, Immunoglobulin Heavy Chain. Hodgkin Disease / genetics. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Caspases / genetics. DNA-Binding Proteins / genetics. Female. Genes, myc. Humans. Immunoglobulin Class Switching. Immunoglobulin Constant Regions / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Proteins / genetics. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079453.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Constant Regions; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


85. Pahwa P, McDuffie HH, Dosman JA, McLaughlin JR, Spinelli JJ, Robson D, Fincham S: Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides. J Occup Environ Med; 2006 Mar;48(3):264-74
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma, multiple myeloma, soft tissue sarcomas, insect repellents, and phenoxyherbicides.
  • OBJECTIVE: The objective of this study was to determine if there is an additional risk of developing Hodgkin lymphoma, multiple myeloma, or soft tissue sarcoma as a consequence of exposure to a combination of phenoxyherbicides, rubber gloves, DEET (N, N-diethyl-m-toluamide), and sunlight compared with each of the individual chemicals.
  • RESULTS: No additional risk from these combinations of exposures of developing these three types of tumor was found in contrast to non-Hodgkin lymphoma.
  • CONCLUSIONS: The mechanisms by which phenoxyherbicides contribute to the risk of multiple myeloma and non-Hodgkin lymphoma may be different.


86. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, FHDH ANRS CO4 ANRS CO141: Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr; 2009 Feb 1;50(2):206-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
  • Here we compared the risks of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in IL-2-treated and IL-2-untreated HIV-infected patients.
  • CONCLUSIONS: In this large observational study, IL-2 therapy did not increase the risk of lymphoma, either NHL or HL, in HIV-infected patients.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / epidemiology. Interleukin-1 / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Female. France. Hospitals. Humans. Incidence. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131886.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong M; Lang JM; Lascaux A; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard J; Pavie J; Pialoux G; Pilorgé F; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard J; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Abgrall S; Grabar S; Guiguet M; Lanoy E; Lièvre L; Mary-Krause M; Potard V; Selinger-Leneman H; Fichou J; Bouvet E; Crickx B; Ecobichon J; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Salmon D; Sicard D; Auperin I; Gilquin J; Roudière L; Viard J; Boué F; Fior R; Delfraissy J; Goujard C; Jung C; Lesprit P; Desplanque N; Meynard JL; Meyohas M; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel J; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine J; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont J; Moreau J; Gastaut J; Retornaz F; Soubeyrand J; Allegre T; Blanc P; Galinier A; Ruiz J; Lepeu G; Granet-Brunello P; Esterni J; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang J; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand M; Yazdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M; Lévy Y; Aboulker J; Bursachi P; Delfraissy J; Saïdi Y; Lascaux A; Saïdi S; Commoy M; Chêne G; Viard JP; Molina J; Tubiana R; Lascaux AS; Berdah M; Jung C; Molina J; Lafaurie M; Schnell-Niedbalski L; Oksenhendler E; Gérard L; Delfraissy J; Goujard C; Chaix F; Rannou MT; Tegna L; Tisne-Dessus D; Jeanblanc F; Beck-Wirth G; Benomar M; Verdon R; Bazin C; Goubin P; Girard P; Boudraa C; Sebire M; Viard J; Maignan A; Tubiana R; Katlama C; Curjol A; Fabre G; Trepo C; Brochier C; Thoirain V; Bloch M; Mortier E; Dupon M; Raymond I; Ragnaud JM; Raymond I; Sellier P; Magnier JD; Simon A; Iguerstira M; Gastaut J; Dalmas AM; Aboulker J; Guéguen S; Circosta S; Mourlhou P; Saouzanet-Harel M; Izard S; Saïdi Y
  •  go-up   go-down


87. Tavani A, Bosetti C, Franceschi S, Talamini R, Negri E, La Vecchia C: Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma. Eur J Cancer Prev; 2006 Oct;15(5):453-7
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma.
  • Individuals diagnosed with skin cancer have elevated risk of non-Hodgkin lymphoma, and those with non-Hodgkin lymphoma have excess rates of various types of skin cancers.
  • Sunshine and other sources of ultraviolet radiation are major risk factors for skin cancer, and hence a potential common link between skin cancer and non-Hodgkin lymphoma.
  • We analyzed the relationship between occupational exposure to ultraviolet radiation and the risk for non-Hodgkin lymphoma using data from a case-control study conducted in Northern Italy between 1985 and 1997.
  • Cases were 446 patients with histologically confirmed incident non-Hodgkin lymphoma, and controls were 1295 patients admitted to hospital for acute non-neoplastic, non-immunological conditions.
  • Our study found no association between occupational exposure to ultraviolet radiation and the risk of non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Occupational Exposure. Ultraviolet Rays
  • [MeSH-minor] Adult. Case-Control Studies. Confidence Intervals. Female. Humans. Male. Odds Ratio. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912575.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


88. Heran NS, Yong RL, Heran MS, Yip S, Fairholm D: Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report. J Neurosurg Spine; 2006 Jul;5(1):61-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intradural extraarachnoid hodgkin lymphoma of the cervical spine. Case report.
  • An intraoperative pathological examination determined the lesion to be a Hodgkin lymphoma.
  • To the authors' knowledge this is the first reported case of a presumed primary intradural extraarachnoid Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cervical Vertebrae. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850958.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • The disease manifests with leukaemia in greater than two thirds of patients, while the remaining patients have a lymphomatous form.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • Organomegaly, skin involvement, circulating atypical lymphocytes ("flower" cells) with a CD4+ CD25+ phenotype and hypercalcaemia are the most common disease features.
  • The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I.
  • The differential diagnosis of ATLL includes other mature T-cell neoplasms such as T-cell prolymphocytic leukaemia (T-PLL), Sézary syndrome (SS), peripheral T-cell lymphomas and occasionally healthy carriers of the virus or Hodgkin disease.
  • The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms.
  • Despite major advances in understanding the pathogenesis of the disease, management of these patients remains a challenge for clinicians as they do not respond or achieve only transient responses to therapies used in high-grade lymphomas.
  • The use of antiretroviral agents such as zidovudine in combination with interferon-alpha, with or without concomitant chemotherapy, has shown activity in this disease with improvement in survival and response rate.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunophenotyping. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


90. Jacobs BL, Blodgett TM, Monaco SE, Hrebinko RL, Jacobs SA: Adrenal insufficiency as presenting feature of non-Hodgkin lymphoma. Can J Urol; 2010 Oct;17(5):5411-4
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal insufficiency as presenting feature of non-Hodgkin lymphoma.
  • Lymphomatous involvement of an adrenal gland during the course of a lymphoma is common, but a primary presentation of adrenal insufficiency in a patient with lymphoma involving both adrenal glands is rare.
  • We describe a 36-year-old man with non-Hodgkin lymphoma (NHL) who presented with adrenal insufficiency.
  • His evaluation consisted of several imaging modalities, including positron emission tomography-computed tomography (PET-CT) scans, which were helpful in defining the extent of disease prior to treatment and in monitoring the patient's response to treatment.
  • Our case illustrates the importance of preoperative evaluation to exclude a lymphoma, particularly in patients with bilateral renal and/or adrenal masses.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Insufficiency / etiology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2010 Oct;17(5):5414 [20974042.001]
  • (PMID = 20974041.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


91. Ho L, Valenzuela D, Negahban A, Wassef H: Primary spinal epidural non-Hodgkin lymphoma demonstrated by FDG PET/CT. Clin Nucl Med; 2010 Jul;35(7):487-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary spinal epidural non-Hodgkin lymphoma demonstrated by FDG PET/CT.
  • We report the F-18 fluorodeoxyglucose positron emission tomography/computed tomography appearance of a biopsy-proven primary epidural non-Hodgkin lymphoma involving the lower cervical and upper thoracic spine with a small hypermetabolic right middle lobe nodule in a 33-year-old man.
  • Primary spinal epidural non-Hodgkin lymphoma is a rare form of malignancy, constituting approximately 0.1% to 3.3% of all lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Spinal Cord Neoplasms / radiography. Spinal Cord Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20548138.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Seshadri P, Rajan SJ, George IA, George R: A sinister itch: prurigo nodularis in Hodgkin lymphoma. J Assoc Physicians India; 2009 Oct;57:715-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sinister itch: prurigo nodularis in Hodgkin lymphoma.
  • She was subsequently diagnosed to have Hodgkin lymphoma on lymph node biopsy.
  • Skin changes in lymphoma can precede other clinical symptoms by months.
  • [MeSH-major] Hodgkin Disease / complications. Paraneoplastic Syndromes / etiology. Prurigo / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Glucocorticoids / therapeutic use. Humans. Vinblastine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Prurigo nodularis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20329432.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glucocorticoids; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


93. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer; 2005 Nov;45(6):753-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
  • Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma.
  • The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin lymphoma, childhood.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15929129.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA13697; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 157
  •  go-up   go-down


94. Clarke CA, Glaser SL, Keegan TH, Stroup A: Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev; 2005 Jun;14(6):1441-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California.
  • Hodgkin's lymphoma occurrence has long been noted to associate with higher socioeconomic status (SES).
  • However, the Hodgkin's lymphoma-SES association has not been examined recently or across important, possibly etiologically distinct, patient subgroups.
  • In approximately 150 million person-years of observation in the multiethnic population of California, we examined the association of Hodgkin's lymphoma incidence with a composite measure of neighborhood-level SES in patient subgroups defined by age, sex, race/ethnicity, and Hodgkin's lymphoma histologic subtype.
  • Using population-based cancer registry data on 3,794 Hodgkin's lymphoma patients diagnosed 1988 to 1992 and 1990 census data, we assigned a previously validated, multidimensional SES index to census block groups of patient residence.
  • Positive neighborhood SES gradients in Hodgkin's lymphoma incidence were observed only in young adults (ages 15-44 years at diagnosis) with nodular sclerosis Hodgkin's lymphoma and older adult (ages > or =45 years) White and Hispanic males with mixed cellularity Hodgkin's lymphoma.
  • For young adults, associations were marked in Hispanic and Asian women, weaker in Hispanic and White men and White women, and subtle to nonexistent in Blacks and Asian men.
  • Neighborhood SES gradients in Hodgkin's lymphoma incidence varied by age, sex, race/ethnicity, and histologic subtype, underscoring etiologic complexity in Hodgkin's lymphoma.
  • In California, etiologically relevant exposures for young adult Hodgkin's lymphoma, the most common form, could associate more with race/ethnicity or foreign birthplace than neighborhood SES and may be modified by reproductive or other sex-specific factors.
  • [MeSH-major] Hodgkin Disease / economics. Hodgkin Disease / epidemiology. Registries / statistics & numerical data. Social Class
  • [MeSH-minor] Adolescent. Adult. Aged. California / epidemiology. Child. Child, Preschool. Continental Population Groups. Ethnic Groups. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Residence Characteristics. Risk Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941953.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Constantin V, Socea B, Moculescu C, Sireţeanu G, Popa F: [Enteral non-Hodgkin lymphoma in young age--difficult diagnosis]. Chirurgia (Bucur); 2009 Sep-Oct;104(5):607-10
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enteral non-Hodgkin lymphoma in young age--difficult diagnosis].
  • Among all histopathologic forms of malignant colonic tumors treated in our Clinic, lymphoma is the fifth as frequency of apparition, respectively the fourth at patients less than 40 years old.
  • We present the case of a 22-years-old patient, having colonic polyposis and multicentric non-Hodgkin lymphoma of the terminal ileum and ascending colon.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Ileal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / diagnosis. Adult. Colectomy / methods. Colon, Ascending / pathology. Diagnosis, Differential. Humans. Male. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19943562.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


96. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL).
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • A variety of new treatment options, some already established for treating adult NHL, await evaluation in childhood NHL.


97. Grubstein A, Givon-Madhala O, Morgenstern S, Cohen M: Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis. J Clin Ultrasound; 2005 Mar-Apr;33(3):140-2
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.
  • We report a case of primary, high-grade non-Hodgkin B-cell lymphoma in the breast of a young woman.
  • Primary breast lymphoma is a rare entity, especially in young females.
  • In previous imaging reports of breast lymphoma, it has always been considered as a mass, though the presence of markedly hypoechoic regions that look like fluid collections is a well known sonographic characteristic of lymphoma.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography. Mastitis / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Mammary


98. Kumar R, Xiu Y, Dhurairaj T, Yu JQ, Alavi A, Zhuang H: F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med; 2005 Apr;30(4):246-8
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast.
  • The breast is an uncommon site of development of extranodal non-Hodgkin lymphoma (NHL).
  • A 36-year-old woman diagnosed with NHL underwent multimodality imaging for staging of the disease.
  • Although rare, breast involvement characterized by increased FDG uptake can occur in patients with lymphoma.
  • This case highlights the role of FDG PET in patients with suspected lymphoma in dense breasts that can be missed by CT scan and mammogram.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma, B-Cell / radionuclide imaging. Positron-Emission Tomography / methods. Rare Diseases / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764881.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


99. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • [Transliterated title] Linfomas no Hodgkin en patología cérvico-facial.
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Gurol Y, Kipritci Z, Selcuk NA, Koc Y, Kocagoz S: Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report. Prague Med Rep; 2008;109(1):19-22
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacillus circulans paracardiac infection in non-hodgkin lymphoma--a case report.
  • A case report is presented concerning Bacillus circulans paracardiac infection in a 27 year old woman with non-hodgkin lymphoma.
  • [MeSH-major] Bacillaceae Infections / diagnosis. Immunocompromised Host. Lymphoma, Non-Hodgkin / microbiology. Mediastinal Diseases / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097386.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down






Advertisement